CP Guojian Pharmaceutical
China - ShanghaiPharmaceutical
Focus: CP Guojian Pharmaceutical is a Shanghai-based antibody drug specialist founded in 2019, operating as a clinical-stage biotech focused on monoclonal antibody development.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Open Jobs
0
About CP Guojian Pharmaceutical
AI assessmentNot HiringNo open roles listed right now. Follow CP Guojian Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Progress-free SurvivalClinical Trials (1)
NCT01291667Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
N/AHelp build intelligence for CP Guojian Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.